Edwards Lifesciences downgraded to Sell from Neutral at UBS UBS downgraded Edwards Lifesciences due to the slower than expected U.S. Sapien launch and European deceleration. Price target lowered to $80 from $95.
Edwards price target raised to $151-$152 from $135-$140 at Wells Fargo Wells Fargo increased its price target on Edwards Lifesciences as the firm believes that the company's roughly in-line 2015 guidance announced yesterday is conservative.The firm also notes that the company raised its long-term TAVR market assumption to over $3B in 2019. The firm keeps an Outperform rating on the shares.
Edwards Lifesciences announces investments in CardioKinetix Edwards made a structured investment in CardioKinetix, a privately held medical device company pioneering a catheter-based treatment for heart failure. This transaction increases Edwards' existing minority interest in CardioKinetix and provides an option to purchase the remaining outstanding shares for a future payment, plus additional milestone payments based on future regulatory and reimbursement approvals. In the second investment, the company acquired intellectual property that broadens its transcatheter mitral valve development efforts. Additional details of both investments were not disclosed.